Compare Global X Cloud Computing ETF (CLOU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cloud Computing ETF vs Recursion Pharmaceuticals Inc — how do they compare? Global X Cloud Computing ETF trades at $27.75, while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: Global X Cloud Computing ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CLOU | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $28.09 | $6.79 |
52-Week Low | $17.60 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLOU, the Global X Cloud Computing ETF, trades at $27.83, down 0.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides diversified exposure to cloud computing stocks, with top holdings like Snowflake and Datadog showing strong non-AI growth drivers. Recent news highlights long-term growth potential beyond AI hype, supported by customer expansion and resilient subscription revenues.
Outlook remains positive for long-term investors due to structural growth in cloud adoption, though short-term risks include high valuations and sector volatility. Key opportunities lie in business diversification and profitability improvements among holdings, while risks involve competitive pressures and macroeconomic sensitivity affecting tech stocks.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
